Quest Diagnostics
 |
|
| Public | |
| Traded as | : DGX S&P 500 Component |
| Industry | Health care |
| Founded | New York City, United States (1967) |
| Founder | Paul Brown |
| Headquarters | Madison, New Jersey, United States |
|
Area served
|
United States, Brazil, Mexico, United Kingdom, India |
|
Key people
|
Steve Rusckowski (CEO) |
| Revenue |
 US$7.5 Billion <s。冖.93·、r·冖n万分mall>(2015) |
|
US$1.4 Billion (2015)
|
|
|
US$0.7 Billion(2015)
|
|
| Total assets |
US$10.0 Billion(2015)
|
| Total equity |
US$4.7 Billion (2015)
|
|
Number of employees
|
44,000 (2015) |
| Website | QuestDiagnostics.com |
Quest Diagnostics Incorporated is a Fortune 500 company providing clinical laboratory services with headquarters in Madison, New Jersey. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name on December 31, 1996. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico and a laboratory in India and also has collaborative agreements internationally with various hospitals and clinics. It is a member of the Fortune 500 and the S&P 500, with corporate headquarters located in Madison, New Jersey. The company has approximately 44,000 employees, generates more than $7 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders.
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical lab for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state’s Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
...
Wikipedia